Dr. Reddy's Laboratories/$RDY
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Dr. Reddy's Laboratories
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (about 20% of its generics sales), Russia (10%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.
Ticker
$RDY
Sector
Primary listing
NYSE
Employees
27,811
Headquarters
Hyderabad, India
Website
RDY Metrics
BasicAdvanced
$12B
18.94
$0.77
0.38
$0.07
0.49%
Price and volume
Market cap
$12B
Beta
0.38
52-week high
$16.19
52-week low
$12.26
Average daily volume
935K
Dividend rate
$0.07
Financial strength
Current ratio
1.893
Quick ratio
1.156
Long term debt to equity
1.441
Total debt to equity
13.751
Dividend payout ratio (TTM)
11.73%
Interest coverage (TTM)
23.73%
Profitability
EBITDA (TTM)
1,013.569
Gross margin (TTM)
57.65%
Net profit margin (TTM)
16.99%
Operating margin (TTM)
21.73%
Effective tax rate (TTM)
25.44%
Revenue per employee (TTM)
$136,300
Management effectiveness
Return on assets (TTM)
9.71%
Return on equity (TTM)
17.71%
Valuation
Price to earnings (TTM)
18.942
Price to revenue (TTM)
3.214
Price to book
3.09
Price to tangible book (TTM)
4.47
Price to free cash flow (TTM)
70.818
Free cash flow yield (TTM)
1.41%
Free cash flow per share (TTM)
0.207
Dividend yield (TTM)
0.49%
Forward dividend yield
0.49%
Growth
Revenue change (TTM)
15.86%
Earnings per share change (TTM)
2.18%
3-year revenue growth (CAGR)
15.43%
10-year revenue growth (CAGR)
8.30%
3-year earnings per share growth (CAGR)
23.97%
10-year earnings per share growth (CAGR)
9.77%
3-year dividend per share growth (CAGR)
10.06%
10-year dividend per share growth (CAGR)
7.18%
What the Analysts think about RDY
Analyst ratings (Buy, Hold, Sell) for Dr. Reddy's Laboratories stock.
Bulls say / Bears say
Dr. Reddy’s aims to roll out a generic version of semaglutide (Wegovy) in 87 countries starting next year, setting the stage to tap into the booming $150 billion obesity drug market by the early 2030s.
The company’s Q2 revenue from Europe more than doubled, bolstered by robust demand for nicotine replacement therapy products acquired from Haleon in 2024, highlighting successful expansion beyond traditional generics.
Management expects Indian generic drug makers, including Dr. Reddy’s, to stay competitive in spite of proposed U.S. tariffs, citing low-cost manufacturing and geographic flexibility that help protect margins across key markets.
Dr. Reddy’s Q2 net profit of ₹14.18 billion was just below analysts’ expectation of ₹14.94 billion, reflecting ongoing pricing pressures and intense competition that reduced overall earnings.
North America sales dropped 11.3% in the June quarter as price erosion affected key products including generic Lenalidomide, and additional revenue pressure is likely once Revlimid’s patent expiry in 2026 leads to more competition.
Novo Nordisk has sued Dr. Reddy’s for patent infringement over its planned generic semaglutide, exposing the company to legal risks that could delay launch and add costs.
Data summarised monthly by Lightyear AI. Last updated on 2 Sept 2025.
RDY Financial Performance
Revenues and expenses
RDY Earnings Performance
Company profitability
RDY News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Dr. Reddy's Laboratories stock?
Dr. Reddy's Laboratories (RDY) has a market cap of $12B as of September 16, 2025.
What is the P/E ratio for Dr. Reddy's Laboratories stock?
The price to earnings (P/E) ratio for Dr. Reddy's Laboratories (RDY) stock is 18.94 as of September 16, 2025.
Does Dr. Reddy's Laboratories stock pay dividends?
Yes, the Dr. Reddy's Laboratories (RDY) stock pays dividends to shareholders. As of September 16, 2025, the dividend rate is $0.07149 and the yield is 0.49%. Dr. Reddy's Laboratories has a payout ratio of 11.73% on a trailing twelve-month basis.
When is the next Dr. Reddy's Laboratories dividend payment date?
The next Dr. Reddy's Laboratories (RDY) dividend payment date is unconfirmed.
What is the beta indicator for Dr. Reddy's Laboratories?
Dr. Reddy's Laboratories (RDY) has a beta rating of 0.38. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.